The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

PURPOSE: Proteasome-inhibiting drugs (PI) are gaining importance in hematologic oncology. The proteasome carries three proteolytically active subunits (β1, β2, β5). All established PI (bortezomib and carfilzomib), as well as experimental drugs in the field (dalanzomib, oprozomib, and ixazomib), by d...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraus, Johannes, Kraus, Marianne, Liu, Nora, Besse, Lenka, Bader, Jürgen, Geurink, Paul P., de Bruin, Gerjan, Kisselev, Alexei F., Overkleeft, Herman, Driessen, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515249/
https://www.ncbi.nlm.nih.gov/pubmed/26099967
http://dx.doi.org/10.1007/s00280-015-2801-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515249/
https://www.ncbi.nlm.nih.gov/pubmed/26099967
http://dx.doi.org/10.1007/s00280-015-2801-0

Ejemplares similares